Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $54.94 Average PT from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has earned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $54.94.

NTLA has been the topic of a number of research reports. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Royal Bank of Canada restated an “outperform” rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research report on Thursday, September 19th. William Blair reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday, November 18th. Citigroup dropped their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Wells Fargo & Company decreased their price target on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating on the stock in a research note on Monday, November 18th.

Insider Buying and Selling at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 28,735 shares of company stock worth $349,909 over the last quarter. 3.20% of the stock is currently owned by company insiders.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. EverSource Wealth Advisors LLC grew its stake in shares of Intellia Therapeutics by 763.5% in the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after buying an additional 1,550 shares in the last quarter. Eastern Bank purchased a new position in Intellia Therapeutics during the 3rd quarter valued at about $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics in the 3rd quarter valued at about $54,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Intellia Therapeutics by 27.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after purchasing an additional 794 shares during the period. Finally, KBC Group NV lifted its position in shares of Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $12.02 on Friday. The business’s 50 day moving average price is $13.87 and its 200-day moving average price is $19.10. Intellia Therapeutics has a 1 year low of $11.34 and a 1 year high of $34.87. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.21 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. During the same period in the previous year, the business earned ($1.38) earnings per share. The business’s revenue for the quarter was down 24.1% on a year-over-year basis. On average, sell-side analysts expect that Intellia Therapeutics will post -5.12 earnings per share for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.